<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Patient-Derived Xenografts (PDXs) – A Powerful Preclinical Tool for Immuno-Oncology Research

Jul 7, 2022 1:30:00 PM / by Champions Oncology posted in Solid Tumor Oncology, Immuno-Oncology

Patient-derived xenograft (PDX) mouse models have become an essential part of the preclinical immuno-oncology toolbox. These models implant patient-derived tumor tissue into immunocompromised mice and facilitate preclinical studies that characterize tumor biology and anti-tumor responses mediated by adoptive cell therapies or novel immuno-oncology drugs.

Read More →